615 completed, 88 terminated, 80 unknown, 31 recruiting. 884 Phase 2, 111 Phase 1, 74 Phase 3.
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) ALN-CIDEB, Placebo - Alcohol-Associated Liver Disease, ALD | Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 120 | 2026-12-09 | 2026-11-12 |
| A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients Entecavell ODT - Hepatitis B Virus, Liver Transplant | Phase 2 | Not yet recruiting | Jongman Kim | 82 | 2026-12-01 | 2026-10-28 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, Placebo, TVAX-008 - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Ausper Biopharma Co., Ltd. | 105 | 2026-10-31 | 2026-10-19 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB) HT-101 + HT-102, HT-101 placebo + HT-102 placebo - Chronic Hepatitis B Virus Infection | Phase 2 | Not yet recruiting | Suzhou HepaThera Biotech Co., Ltd. | 120 | 2026-10-30 | 2026-11-05 |
| Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues YKYY013, YKYY013 Placebo - HBV (Hepatitis B Virus) | Phase 2 | Not yet recruiting | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 120 | 2026-10-30 | 2026-11-12 |
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| Severe Hepatitis Intervention With Emapalumab for Liver Disease Emapalumab - Hepatitis | Phase 2 | Not yet recruiting | Children's Healthcare of Atlanta | 28 | 2026-09-01 | 2026-08-04 |
| Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions AHB-137 - Hepatitis B, Chronic | Phase 2 | Recruiting | AusperBio Therapeutics Inc. | 70 | 2026-09-01 | 2026-10-29 |
| Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B GST-HG141, GST-HG131, GST-HG141 Placebo - Chronic Hepatitis B | Phase 2 | Recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 80 | 2026-07-10 | 2026-07-17 |
| Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatohepatitis, MASH | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 360 | 2026-07-06 | 2026-11-09 |
| Bepirovirsen Liver Biopsy Study Bepirovirsen, Liver biopsy, Optional Liver biopsy - HEPATITIS B CHRONIC, Hepatitis B Chronic Infection | Phase 2 | Not yet recruiting | National University Health System, Singapore | 30 | 2026-07-01 | 2026-07-10 |
| PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab - Colitis, Hepatitis | Phase 2 | Not yet recruiting | Therakos LLC | 112 | 2026-07-01 | 2026-06-02 |
| A-TANGO Phase 2 Study Placebo, TAK-242, G-CSF (Filgrastim) - Acute-On-Chronic Liver Failure, Alcoholic Hepatitis | Phase 2 | Recruiting | Yaqrit Ltd | 78 | 2026-06-29 | 2026-09-21 |
| Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV Glecaprevir/pibrentasvir - Hepatitis C | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2026-06-25 | 2026-08-14 |
| Study of AHB-171 in Chronic Hepatitis B Participants AHB-171 Injection - Hepatitis B, Chronic (CHB) | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 138 | 2026-06-24 | 2026-07-21 |
| A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B AHB-137, Placebo - Chronic Hepatitis B | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 320 | 2026-06-05 | 2026-07-29 |
| Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection HH-006 - Chronic Hepatitis B Virus Infection | Phase 2 | Recruiting | Huahui Health | 45 | 2026-05-14 | 2026-06-15 |
| Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region AHB-137 - Hepatitis B, Chronic | Phase 2 | Recruiting | AusperBio Therapeutics Inc. | 84 | 2026-03-06 | 2026-10-13 |
| A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Therapeutic hepatitis B vaccine, Commercial Hepatitis B vaccine - Chronic Hepatitis b | Phase 1 / Phase 2 | Not yet recruiting | Vaxine Pty Ltd | 40 | 2026-03-01 | 2025-09-22 |
Showing 20 of 884. Sign in to see all of them.
Hepatitis C (339) · Hepatitis C, Chronic (227) · Hepatitis B, Chronic (188) · Hepatitis B (163) · HIV Infections (38) · Liver Diseases (35) · Fibrosis (28) · Hepatitis, Alcoholic (27) · Tetanus (23) · Diphtheria (22) · Liver Cirrhosis (22) · Hepatitis, Chronic (21) · Haemophilus Infections (19) · Poliomyelitis (18)
Digestive System Diseases (878) · Liver Diseases (849) · Infections (809) · Hepatitis, Viral, Human (803) · Virus Diseases (797) · Blood-Borne Infections (775) · Communicable Diseases (772) · RNA Virus Infections (546) · Pathological Conditions, Signs and Symptoms (486) · Pathologic Processes (483) · Flaviviridae Infections (479) · Disease Attributes (447) · Chronic Disease (443) · Hepatitis, Chronic (437)
Ribavirin (230) · peginterferon alfa-2a (134) · Sofosbuvir (56) · entecavir (54) · Tenofovir (44) · peginterferon alfa-2b (34) · daclatasvir (32) · Ritonavir (31) · ledipasvir, sofosbuvir drug combination (26) · telaprevir (23) · Simeprevir (19) · paritaprevir (19) · tenofovir alafenamide (19) · grazoprevir (18) · sofosbuvir-velpatasvir drug combination (18)
Gilead Sciences (76) · GlaxoSmithKline (41) · Merck Sharp & Dohme LLC (41) · Bristol-Myers Squibb (36) · National Institute of Allergy and Infectious Diseases (NIAID) (27) · Hoffmann-La Roche (23) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (21) · Vertex Pharmaceuticals Incorporated (15) · AbbVie (14) · ANRS, Emerging Infectious Diseases (12) · AbbVie (prior sponsor, Abbott) (11) · Ausper Biopharma Co., Ltd. (9) · Boehringer Ingelheim (9) · Janssen Research & Development, LLC (9) · Arrowhead Pharmaceuticals (8)
United States (355) · China (114) · France (113) · Germany (108) · Canada (100) · United Kingdom (92) · Puerto Rico (72) · New Zealand (71) · Spain (71) · South Korea (64) · Australia (60) · Taiwan (60) · Italy (58) · Belgium (51) · Hong Kong (44)
Marc G Ghany, M.D. (7) · Junqi Niu (5) · Robert H. Hyland, DPhil (5) · Asem Elfert, MD (4)
PMID 28193518, PMID 30012435, PMID 30664876, PMID 30923816, PMID 30977945, PMID 37011138, PMID 41586499, PMID 20091678, PMID 20657177, PMID 24154738, PMID 24209977, PMID 24983020, PMID 25164700, PMID 25445400, PMID 25830171, PMID 26596948, PMID 26683763, PMID 26691547, PMID 26752189, PMID 27257978, PMID 28340322, PMID 28412293, PMID 28802814, PMID 28802816, PMID 30850240, PMID 31108015, PMID 31568620, PMID 35179437, PMID 39950613, PMID 41042426, PMID 11605686, PMID 12620148, PMID 15282352, PMID 15316341, PMID 15374882, PMID 15563253, PMID 15667486, PMID 15685543, PMID 15763232, PMID 15820563, PMID 15867490, PMID 15940636, PMID 15994231, PMID 16115185, PMID 16439867, PMID 16544259, PMID 16628625, PMID 16871563, PMID 16912304, PMID 16987047
2014 (18), 2015 (13), 2016 (13), 2009 (11), 2019 (9), 2023 (6), 2017 (5), 2008 (4), 2018 (3), 2004 (2), 2025 (2), R01DA026727 (2), U01AA021788 (2), U01AA021886 (2), U01AA021891 (2)